The pattern visual evoked potential by Brigell, Mitchell et al.
Documenta Ophthalmologica 86: 65-79, 1994. 
© 1994 Kluwer Academic Publishers. Printed in the Netherlands. 
The pattern visual evoked potential 
A multicenter study using standardized techniques 
MITCHELL BRIGELL, 1 DAVID I. KAUFMAN, 2 PHYLLIS BOBAK 3 
& AHMAD BEYDOUN 4 
1Department of Neurology, Loyola University Chicago, Maywood, IL ; 2Neuro- 
Ophthalmology Unit, Michigan State University, East Lansing; 3Department of 
Ophthalmology, University of Illinois at Chicago; 4Department of Neurology, University of 
Michigan, Ann Arbor 
Accepted 12 October 1993 
Key words: Clinical trials, Demyelination, Optic neuropathy, Visual evoked potential 
Abstract. The peak latency of the pattern-reversal visual evoked potential is a sensitive measure 
of conduction delay in the optic nerve caused by demyelination. Despite its clinical utility, the 
pattern-reversal visual evoked potential has not previously been used in multicenter clinical 
trials, presumably because of difficulty in standardizing conditions between centers. To 
establish whether the pattern-reversal visual evoked potential could be adequately standardized 
for use as a measure in multicenter therapeutic trials for optic neuropathy or multiple sclerosis, 
stimulus and recording variables were equated at four centers and pattern-reversal visual 
evoked potentials were recorded from 64 normal subjects and 15 patients with resolved optic 
neuritis. Results showed equivalent latency and amplitude data from all centers, suggesting that 
stimulus and recording variables can be satisfactorily standardized for multicenter clinical trials. 
N70 and P100 peak latencies and N70-P100 interocular amplitude difference were sensitive 
measures of resolved optic neuritis. 
Abbreviations: ANOVA - analysis of variance; ON - optic neuritis 
Introduction 
The pattern visual evoked potential (PVEP) is widely recognized as a 
sensitive measure of optic nerve demyelination, it has been shown to be 
more sensitive to resolved optic neuritis (ON) than magnetic resonance 
imaging [1-3], contrast sensitivity [4-61, Goldmann perimetry [7] or visual 
acuity [4, 8]. P100 peak latency has been reported to be significantly 
prolonged in approximately 90% of patients with a clinical history of ON 
[4, 9-12], despite recovery of visual function to near-normal levels in most 
patients. It has been suggested that prolonged P100 latency reflects conduc- 
tion delay secondary to demyelination, whereas loss of function is due to 
conduction blockage [13]. In addition, the PVEP has proved to be useful for 
the diagnosis of multiple sclerosis by establishing subclinical demyelination 
of the optic nerve. A survey of the literature [14] indicated that 51% of 
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patients with multiple sclerosis without a clinical history of ON have 
abnormal P100 latencies. 
Given the sensitivity of the PVEP to ON and the independence of P100 
latency from performance measures, its potential usefulness as an outcome 
measure in a clinical trial such as the recently completed ON treatment trial 
[15] is apparent. However, despite its clinical utility, the PVEP has never 
been used as part of a multicenter clinical trial. This may reflect concerns 
regarding standardization of stimulation and recording variables known to 
affect the PVEP. In fact, latency and amplitude of the PVEP can be affected 
by many stimulus features, including mean luminance [8, 16], contrast [17, 
18] and spatial frequency [19, 20], as well as by the amplifier filter settings 
and sample rate of the analog-to-digital converter [14]. Thus, for a 
multicenter PVEP study to be successful, it is important to equate the 
pattern stimulus and data acquisition variables as nearly as possible across 
centers. The purpose of this study was to assess the feasibility of obtaining 
PVEP data in a multicenter setting and to demonstrate the sensitivity of this 
test to resolved ON. A rationale for obtaining PVEP data in therapeutic 
trials for optic neuropathy and multiple sclerosis is presented that empha- 
sizes the sensitivity of the PVEP to conduction delays in functioning 
neuronal pathways. 
Subjects and methods 
Centers. Four centers participated in the study: Loyola University of 
Chicago, Michigan State University (East Lansing), the University of 
Illinois at Chicago and the University of Michigan (Ann Arbor). 
Subjects. Each center tested 16 normal subjects, eight men and eight 
women, between the ages of 18 and 45 years. Exclusion criteria included any 
history of ophthalmologic or neurologic disease, best corrected visual acuity 
of worse than 20/20 and greater than 4 diopters of negative correction. In 
addition, 15 patients with a history of unilateral ON were tested (four at 
each of three centers and three at the remaining center). Exclusion criteria 
for patients were a history of other ophthalmologic disease, history of 
neurologic disease other than multiple sclerosis, best corrected visual acuity 
of worse than 20/25, greater than 4 diopters of negative correction and an 
episode of ON within the last 6 months. The study protocol was approved 
by the Institutional Review Board of each of the four institutions, and 
informed consent was obtained from all subjects before their participation. 
The number of subjects tested was based on statistical power calculations. 
For comparison of normative latency data across centers, an n of 16 affords 
a power of 80% (alpha --- 0.05; 3 and 60 degrees of freedom) to detect a 2-ms 
difference between centers assuming a 5-ms standard deviation [21]. The 
choice of a 2-ms criterion was based on previous studies of test-retest 
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reliability of the PVEP at single centers [22, 23, 24, 25], which show mean 
P100 latency retest differences of 2 to 3 ms. Thus, testing of 16 subjects per 
center provides sufficient power to detect differences between centers 
greater than that expected from the intrinsic variability of the test. Test- 
retest P100 amplitude measurements show a mean difference of 1.5 ~V [26]. 
An n of 16 yields a power of 86% to detect a difference of 1.5 ~V between 
four centers using a alpha level of 0.05 and an estimated amplitude standard 
deviation of 3.6 pN (see discussion). The literature comparing PVEPs in 
normal subjects to those with a history of ON suggests a mean P100 latency 
delay of 20-30 ms from the affected eye, with an approximately fourfold 
increase in the standard deviation of the measure [27-31]. With a conserva- 
tive estimate of a 20-ms standard deviation in the ON group, a comparison 
of 64 normal subjects and 15 patients provides a power of 96% (alpha = 
0.05) to detect a 20-ms difference in mean P100 latency of ON and normal 
populations. Our sample size had a 90% power to detect the 1.6-pN effect 
(standard deviation = 1.9) of ON on P100 amplitude reported by Shahrokhi 
et al. [27]. 
Stimuli. Stimuli at all four centers were generated on commercially available 
video monitors. Spatial and luminance characteristics of the stimuli were 
equated across centers. Stimuli were checkerboard patterns that were phase 
reversed at 1.8 reversals per second. Check element sizes of 15', 30' and 60' 
were used. Mean luminance of the patterns was 99.25 cd/m 2, and contrast 
was 92%. Each system was adjusted to appropriate luminance levels by 
means of the same UDT-61 photometer .  
To equate check sizes it was necessary to allow field size to vary across 
centers, as a variety of monitors were employed. The visual angle subtended 
by the stimulus field ranged in horizontal dimension from 16 ° at Loyola 
University of Chicago to 32 ° at the University of Michigan. Field size was 
not thought to be a critical variable, as previous studies have shown that the 
PVEP is primarily generated by the central 10 ° of the visual field [32, 33]. In 
a preliminary study to dissociate check size and field size effects, a subject 
was tested with both 15' and 30' checks at viewing distances of 85 and 
170 cm. Although the field size at the nearer distance was twice that of the 
far distance, PVEP amplitude and latency measures were unaffected. These 
measures were sensitive to angular subtense of the checks, but not to the 
physical size of the pattern on the screen. 
Data acquisition and analysis. Amplifier filter bandpass was set at 1 to 
250 Hz at each center. Sweep duration was 250 ms, and 100 sweeps were 
averaged for each run. The PVEPs were recorded from four channels 
(MO-Fz; MO-A1; inion-Fz; Pz-Fz). Data  were analyzed from an active 
electrode 5 cm above the inion (MO) referenced to an electrode 12cm 
above the nasion (MF) unless waveforms from this channel were unusually 
low in amplitude or had a bifid P100 peak. This was true in only one of the 
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80 subjects of this study (a normal woman). For this subject an active 
electrode at the inion referenced to MF produced higher-amplitude 
waveforms, and this channel was used for analysis. A vertex electrode was 
used as ground. Two replications were obtained at each check size for each 
eye. The order in which eyes were tested and stimuli were presented was 
counterbalanced between subjects. Peak latencies of the N70, P100 and 
N145 components were measured. Amplitudes of the N70-P100 and P100- 
N145 complexes were measured from peak to trough. In addition to 
absolute amplitudes and latencies, interocular differences were determined. 
Statistical comparisons were made by means of a mixed-design analysis of 
variance (ANOVA) for each latency and amplitude measure. Data from 
normal subjects were submitted to a two-eye x four-center x three-check 
size x two-replication equal n ANOVA. The main effect of replications was 
statistically insignificant, and this variable did not interact with any other 
variables. Therefore, this factor will not be discussed further. The variability 
of PVEP latency and amplitude in the normal population was calculated on 
the median of the four values obtained for each stimulus condition (i.e., two 
replications on each of two eyes). This is necessary to obtain an accurate 
estimate of population variability because of the high correlation of 
measures between eyes of an individual and across replications [34]. 
Data for patients with ON and normal subjects were compared by means 
of a similar unequal n model. Clinically affected eyes were grouped for 
analysis and compared to the unaffected eyes of patients. 
Results 
Normal subjects 
The mean latencies of N70, P100 and N145 peaks for each center and for 
each check size are shown in Fig. 1. The similarity of peak latencies across 
the four centers is apparent. P100 peak latency, averaged over check size, 
differed by less than 5 ms between centers. The largest difference in P100 
latency between centers for a single condition was 5.59 ms between the 
University of Michigan and Loyola University of Chicago for 30' checks. 
This difference is only approximately 1 standard deviation away from either 
mean and is not statistically significant (t[15] < 1). No statistically significant 
difference between centers in peak latency of N70, P100 or N145 com- 
ponents was found for any check size. As check size decreased, a 
significant increase in P100 peak latency was obtained [F(2, 54) = 47.07; p < 
0.001]. This effect was expected, as the increase of P100 latency with 
increasing spatial frequency is well documented [20, 35]. A significant check 
size by center interaction was also obtained [F(6,108)= 2.38; p <0.05]. 
This interaction was caused by a slightly larger effect of check size on data 
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Fig. I. Mean peak latency of N70, P100 and N145 components obtained with 15', 30' and 60' 
check stimulation for all normal subjects tested at each of four sites. Error  bars represent 1 
standard deviation. LU = Loyola University of Chicago, MSU = Michigan State University, 
UIC = University of Illinois at Chicago, UM = University of Michigan. 
of results was obtained for N70 peak latency, with comparable latencies 
between centers (maximum latency difference between centers of 4.44 ms), a 
significant increase in peak latency with decreasing check size [F(2, 54)= 
125.81; p <0.001] and a center by check size interaction [F(6, 108)= 3.4l; 
p < 0.011. Peak latency of the Nl45 peak was more variable, and only the 
effect of check size was statistically significant IF(2, 54) = 7.92; p < 0.001]. 
Peak latency difference between eyes was small and showed little 
variation between centers. Across all centers and check sizes, the mean 
interocular peak latency difference was less than 1ms, with a standard 
deviation of 4.04ms. The ANOVAs on N70, P100, and N145 measures 
showed no significant effects of center or check size on interocular peak 
latency difference and no significant interactions. 
Figure 2 shows the mean and standard deviation of N70-P100 and P100- 
N145 amplitudes for each center for all check sizes. Although amplitude 
values are somewhat more variable than latency values both within and 
between centers, no systematic differences between centers were obtained, 
as indicated by the absence of a significant main effect of center for either 
amplitude measure. Mean N70-P100 amplitude was 8.57 ~V over all check 
sizes and subjects. The maximum difference in mean amplitude between 













60' 15' 30' 60' 
NT0-P100  P 1 0 0 - N i 4 5  
Fig. 2. Mean peak-to-peak amplitude of N70-P100 and P100-N145 obtained to 15', 30' and 60' 
checks for all normal subjects tested at each of four sites. Error bars represent 1 standard 
deviation. LU = Loyola University of Chicago, MSU = Michigan State University, UIC = 
University of Illinois at Chicago, UM = University of Michigan. 
amplitude was obtained [F (2 ,54 )=3 .25 ;  p < 0 . 0 5 ] ,  reflecting a 0.50-pN 
lower amplitude for 30' checks than for 15' or 60' checks. No significant 
effects of center or interactions involving center were obtained. The P100- 
N145 mean amplitude was 10.18 txV, and the maximum mean difference 
between centers was 1.60 txV. There were no significant effects of center, 
check size or eye on this variable, and no significant interactions were 
obtained. 
Thus, results of the present study demonstrate that it is possible to 
standardize conditions adequately between centers to equate PVEP norma- 
tive variables. Normative values across all centers are given in Table 1 for 
the stimulus conditions used in this study. 
P V E P  sensitivity to optic neuritis 
PVEPs were obtained from 15 patients with resolved unilateral ON. The 
identical protocol as that used for normal subjects was used to facilitate 
comparison between groups. One patient had no reproducible responses to 
15' check stimulation of her affected eye. No latency data were included for 
this eye for this stimulus, and amplitudes were entered in the database as 
Table I. PVEP normative values (n = 64) 
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Check size 
15' 30' 60' 
N70 peak latency (ms) 78.46 72.04 69.20 
SD 5.42 6.34 6.51 
Mean + 2.5 SDs 92.01 87.89 85.48 
P100 peak latency (ms) 105.43 100.14 101.77 
SD 6.42 6.39 5.91 
Mean + 2.5 SDs 121.48 116.12 116.55 
NT0-P100 amplitude (~xV) 9.86 9.16 9.63 
SD 4.27 3.68 3.84 
Mean - 2.5 SD 0.00 0.00 0.00 
P100 interocular 
latency difference 1 (ms) 0.13 -- 0.60 -- 0.36 
SD 4.43 4.04 3.80 
Mean + 2.5 SDs 11.21 9.50 9.14 
Mean - 2.5 SDs -10.95 -10.70 -9.86 
N70-P100 interocular 
amplitude difference 1 0xV) 0.54 0.11 0.00 
SD 2.01 2.12 1.79 
Mean + 2.5 SD 5.57 5.41 4.48 
Mean - 2.5 SD -4.49 -5.19 4.48 
SD := standard deviation. 
~Right eye minus left eye. 
0.00. Figure 3 shows the mean  P100 peak  latency as a funct ion of  check size 
for  normal  subjects and affected and unaf fec ted  eyes of  pat ients  with a 
unilateral  history of  ON,  averaged over  all centers.  The  large effect of  O N  
on this measure  for  all check sizes is evident.  Interest ingly,  the mean  peak  
latency of  the P100 for compan ion  eyes of  patients with unilateral  O N  was 
4.32 ms longer  than that of  normal  subjects for  15' checks and 5.45 ms 
longer  for  30'  checks,  suggesting the possibility of  subclinical demyel ina t ion  
in some of  these optic nerves. Statistical analysis showed a significant main  
effect of  group (pat ient  versus control)  on  P100 peak  latency [F(1, 7 7 ) =  
4.12; p < 0 . 0 5 ]  and a significant g roup  by eye interact ion [ F ( 1 , 1 5 4 ) =  7.11; 
p < 0.01], reflecting a significant difference be tween  affected and fellow eyes 
of  patients but no significant difference be tween  eyes in the normal  group.  It 
is impor tan t  to note  that  the P100 peak  latency delays observed  in eyes with 
resolved O N  are not  subtle. Figure 4 shows that  when  a clinical cri terion for  
delay of  2.5 s tandard  deviations above  normal  mean  is employed ,  12 of  16 
eyes with a history of  O N  are abnormal  for  at least one check size, and two 
of  16 clinically unaffec ted  eyes are abnormal .  Bo th  clinically unaf fec ted  eyes 
with abnormal  P100 latencies were abnormal  for  all check sizes. A similar 
pat tern  of  results was observed  for N70 peak  latency, a l though the main  
effect of  g roup  did not  reach statistical significance for  this measure .  
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Fig. 3. Mean P100 peak latency as a function of check size for normal eyes and affected and 
unaffected eyes of patients with resolved unilateral ON. Error bars represent 1 standard error 
of the mean (SEM). The SEMs for normal subjects are smaller than the date points. 
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Fig. 4. S c a t t e r  p lo t  o f  P100  l a t enc ie s  as a f u n c t i o n  o f  c h e c k  size in a f f e c t e d  a n d  u n a f f e c t e d  eyes  
of patients with unilateral resolved ON and normal controls. Error bars indicate the upper and 
lower limits of normal (Mean-+ 2.5 standard deviations). 
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Analysis of interocular peak latency differences showed a large effect of 
ON on all peak latency measures, with a mean difference in P100 latency of 
17.9 ms between affected and unaffected eyes. This measure added to the 
sensitivity of the PVEP, as two patients with normal P100 latency from the 
affected eye had significant interocular latency differences. Patient interocu- 
lar latency differences and normative values are compared in Fig. 5. 
Amplitude of the PVEP was also sensitive to resolved ON. As can be 
seen in Fig. 6, amplitude was reduced in eyes with ON for all check sizes. 
This reduction in amplitude became more prominent as check size de- 
creased, as reflected by a significant group by eye by check size interaction 
[F (2,308) = 3.84; p < 0.05]. A similar pattern of results was obtained for 
P100-N145 amplitude [F(2,308)= 4.47; p < 0.05]. Despite the statistically 
significant effect of ON on PVEP amplitude, no clinically significant 
abnormalities were obtained with a 2.5-standard deviation criterion. As can 
be seen in Table 1, the lower limit of normal amplitude goes through 
0.00 IxV, precluding detection of significant amplitude abnormalities. How- 
ever, the use of interocular amplitude difference does allow detection of 
clinically significant amplitude abnormalities. 
Figure 7 shows interocular amplitude differences from patients in relation 
to the normal range for 30' check stimuli. Only three of 16 patients had a 
clinically significant interocular amplitude difference. However, N70-P100 
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Fig. 5. Scatter plot of interocular latency difference of the P100 for patients with resolved 
unilateral ON and normal controls. Error bars indicate the upper and lower limits of normal 
(mean-+ 2.5 standard deviations). 
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Fig. 5. Mean NT0-P100 amplitude as a function of check size for normal eyes and affected and 
unaffected eyes of patients with resolved unilateral ON. Error bars represent 1 standard error 
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Fig. 7. Scatter plot of N70-P100 interocular amplitude difference for patients with resolved 
unilateral ON and normal controls. Error bars indicate the upper and lower limits of normal 
(mean -+ 2.5 standard deviations). 
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amplitude was reduced in the affected eye by a mean of 1.62 fxV when 
compared to the unaffected eye. This interocular amplitude difference was 
significantly larger than the normal mean interocular difference of 0.11 IxV 
IF (1,77)= 5.56; p < 0.05]. The reduction of amplitude in affected eyes is 
consistent with some conduction blockage or axonopathy after ON, al- 
though temporal dispersion to demyelination could also cause reduced 
amplitude. 
Discussion 
The results of the present study indicate that comparable PVEP data can be 
obtained at multiple centers if stimulus and recording conditions are equated 
across centers. Latencies of the N70 and P100 peaks showed the least 
variability across normal subjects and were sensitive to a previous episode of 
ON. Amplitude was variable across subjects. However, interocular am- 
plitude difference of N70-P100 was less variable than absolute amplitude in 
normal subjects and was shown to be sensitive to unilateral ON. Although 
the finding that normative PVEP values are comparable between centers if 
stimulus and recording variables are controlled may not be surprising, it 
should be noted that the reason that the PVEP was not used as an outcome 
measure in the recently completed ON treatment trial was concern regard- 
ing what would constitute adequate standardization across centers (R.W. 
Beck, personal communication). Results of the current study suggest that 
the PVEP can be equated between centers with calibration of stimulus mean 
luminance, contrast and check size, adjustment of amplifier variables to 
comparable values and use of a standard test protocol. The results also 
suggest that field size is not a critical variable for fields greater than 16 °, 
probably due to magnification of the central visual field in visual cortex. 
The variability of our normative data was similar to values obtained in 
normative studies conducted at a single laboratory. In a review of 28 studies 
reporting normative P100 latency data on checkerboard PVEPs, standard 
deviations ranged from 2.92 ms [36] to 9.0 ms [29], with a mean of 5.28 ms. 
The standard deviations of P100 latency shown in Table 1 are within this 
range. Published normative P100 amplitude standard deviations in 13 studies 
ranged from 1.5 ~V [31] to 5.3 txV [37], with a mean of 3.52 fxV. The 
standard deviation of amplitude obtained in this study for each of three 
check sizes averaged over four centers was within the range reported for 
single-center studies. Thus, the results of the present study show that the 
PVEP can be adequately standardized for use as an outcome measure in 
multicenter clinical trials. 
Our results also show P100 latency to be a sensitive indicator of optic 
nerve demyelination in eyes with subtle, if any, clinical abnormalities. 
Fourteen (88%) of 16 eyes with a clinical history of ON and visual acuities 
of 20/25 or better had significant abnormalities in P100 latency. Significant 
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abnormality in P100 latency was also found in two 'unaffected' companion 
eyes, suggesting the presence of subclinical demyelination in these optic 
nerves as well. The 24-ms increase in mean P100 latency of eyes with a 
history of ON when compared to the normal mean that was found in this 
multicenter study was similar to that reported in single-center studies 
[27-31]. The standard deviation of 21 ms in P100 latency of the ON group 
was also comparable to findings of previous single-center studies [28, 31]. 
ON was also found to reduce the mean N70-P100 amplitude significantly, 
suggesting that some degree of conduction blockage or axonpathy may have 
occurred in these nerves. Amplitude of the PVEP may be a useful measure 
of the effects of therapy on optic nerve function. Amplitude measures are 
quite variable in the normal population, making them less useful in the 
clinical evaluation of the integrity of an individual optic nerve. However, the 
results of this study showed that significant group differences in PVEP 
amplitude can be readily obtained. Therefore, when efficacy of therapeutic 
regimens is compared, an increase in PVEP amplitude would suggest an 
improvement in physiologic function of the optic nerve. 
In the past, evoked potentials have been criticized as an outcome measure 
in therapeutic trials for multiple sclerosis because of the independence of 
changes in evoked potentials and behavioural recovery [38]. In a prospective 
study of 20 patients with acute ON, Celesia et al. [4] documented the 
dissociation of PVEP latency and visual function. PVEP latency remained 
significantly delayed in 90% of eyes and showed little change after the initial 
visit. In contrast, Snellen acuity, contrast sensitivity, Goldmann perimetry, 
and color vision all showed dramatic improvement during a 6-month period, 
with normal levels of performance reached in 70% to 90% of subjects for 
each measure. It is possible that symptoms occurring during the acute phase 
of ON are primarily due to conduction block caused by vasogenic edema 
[39] and perhaps also to the effects of circulating cytokines, which interfere 
with transmission at the synapse [40]. The residual deficits in spatial vision 
are most likely secondary to permanent conduction block in severely 
demyelinated axons or axonal loss due to wallerian degeneration. Delayed 
PVEP latency, on the other hand, reflects slowed conduction through 
functioning demyelinated axons. Thus, as originally proposed by Halliday & 
McDonald [13], ' . . .  the change in latency [of the PVEP] probably reflects 
closely and accurately the presence of demyelination in a given pathway, 
although the clinical deficit is often more closely related to the associated 
conduction block'. 
If PVEP latency and visual recovery are largely independent, then what is 
the importance of the PVEP as an outcome measure in clinical trials? 
Extensive demyelination results in complete conduction block [41] and 
permanent clinical deficits. If the magnitude of PVEP latency delay is 
correlated with the extent of demyelination, then an effect of therapy on the 
PVEP could have functional significance by implying limitation of the extent 
of demyelination. Reducing demyelination could be beneficial in the case of 
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a second attack of ON by lowering the probabil i ty of conduction blockage 
and severe visual deficits. (In a prospective study in which 60 patients with 
uncomplicated ON were observed for a mean of 7.1 years, Cohen et al. [42] 
repor ted that 15 [25%] had a recurrence of ON.)  
This argument  relies on the assumption that the magnitude of the PVEP 
latency delay is related to the extent of demyelinat ion of the optic nerve. 
Kakisu et al [43] recently repor ted a significant positive correlation between 
PVEP P100 latency and extent of the optic lesion as measured by abnormal  
signal on magnetic resonance images. A similar result has also been  
repor ted regarding the correlation between latency delay of the scalp- 
recorded somatosensory evoked potential  and length of plaque in the 
cervical cord in patients with multiple sclerosis [44]. 
In summary,  the results of the present  study indicate that the PVEP can 
be standardized across centers for use in clinical trials. The PVEP can be an 
important  measure  of effects of  therapy on demyelinative optic neuropathies  
because it represents conduction delays through functioning neurons not 
measured by most behavioral  measures  of visual function. 
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